{{ (moduleVm.actions && moduleVm.changeStatus) ? moduleVm.status : '' }} Newest Lipoglycopeptides for the Management of Acute Bacterial Skin and Skin Structure Infections

Activity Steps

Purpose of Activity

To provide information on the role of lipoglycopeptides and other standardized therapy options used to treat ABSSSIs.

Learning Objectives/Outcomes

After completing this continuing education activity you will be able to:

  1. Outline the epidemiology of ABSSSIs and current therapy and monitoring parameters.
  2. Identify the role of oritavancin and dalbavancin in the treatment of ABSSSIs.
Price: $17.95


  • ANCC 1.5 CH / 1.5 APH
  • DC - BON 1.5 CH
  • FL - BON 1.5 CH
  • GA - BON 1.5 CH

Lippincott Professional Development is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation. This activity is also provider approved by the California Board of Registered Nursing, Provider Number CEP 11749. Lippincott Professional Development is also an approved provider of continuing nursing education by the District of Columbia Board of Nursing, Florida Board of Nursing, and Georgia Board of Nursing, #50-1223.

Awarded Advanced Pharmacology Hours

Test Code: NP1018A
Published: Oct 2018
Expires: 9/3/2021
Required Passing Score: 13/18 (72%)
Authors: Allison M. Bell, PharmD; S. Travis King, PharmD; Katie E. Barber, PharmD; Kim G. Adcock, PharmD; Jamie L. Wagner, PharmD; Kayla R. Stover, PharmD